Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (11)

2024

  1. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

  2. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

    European Journal of Cancer, Vol. 199

2022

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 33, Núm. 6, pp. 616-627

  2. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085

2008

  1. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis

    Osteoporosis International, Vol. 19, Núm. 1, pp. 87-94

2007

  1. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms

    European Neuropsychopharmacology, Vol. 17, Núm. 11, pp. 725-734

2004

  1. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

    Journal of the National Cancer Institute, Vol. 96, Núm. 23, pp. 1751-1761

2003

  1. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

    Clinical Therapeutics, Vol. 25, Núm. 4, pp. 1074-1095

1998

  1. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study

    Clinical Drug Investigation, Vol. 15, Núm. 1, pp. 29-35

1997

  1. Olanzapine in treatment-refractory schizophrenia: Results of an open- label study

    Journal of Clinical Psychiatry, Vol. 58, Núm. 11, pp. 479-483